GoldenGolden
Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim is a pharmaceutical company founded in 1885.

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

May 14, 2020
Boehringer Ingelheim acquires Northern Biologics' Preclinical Cancer Antibody Pipeline.

Acquisitions

Acquisition
Acquired company
Acquisition amount (USD)
Date announced
Acquisition of Actimis Pharmaceuticals by Boehringer Ingelheim
515,000,000
June 17, 2008
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Amr Youssef

Employee

Aaron Graham

Employee

Aashir Awan

Employee

Abbas Shivji

Employee

abdellatif ziane

Employee

Aditya Singh

Employee

Adrian van Alphen

Employee

Adriana Oreskovic

Employee

Agustina Yornet

Employee

Aisling Glennie

Employee

Alan Davis

Employee

Alan Wong

Employee

Albert Lens

Employee

Alberto Delmoral

Employee

Alceu Rodrigues de Freitas Junior

Employee

Alejandro Medici

Employee

Alejandro Piris

Employee

Alex Lincoln-Dodgson

Employee

Alex Pavlenko

Employee

Alexander Dross

Employee

Alicia Alonso- Boyanowski M.Ed

Employee

Alison Chiaramonte

Employee

Alison Fay

Employee

Ana Serafimovic

Employee

Andika Tyastono

Employee

Page 1 of 16
...

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Alex Keown
April 15, 2021
BioSpace
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
BioSpace
April 14, 2021
BioSpace
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim's KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer.
April 13, 2021
BioSpace
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity - read this article along with other careers information, tips and advice on BioSpace
Research and Markets
February 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- The "Global Animal Health Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)" report has been added to...
Boehringer Ingelheim; Cure Genetics
January 18, 2021
www.prnewswire.com:443
/PRNewswire/ -- Cure Genetics announced a collaboration with Boehringer Ingelheim to develop novel Adeno-Associated Virus (AAV) vectorsleveraging Cure...
Aditya Saroha
January 13, 2021
The Hindu
Through this collaboration, Boehringer Ingelheim and Google plan to focus on implementing quantum computing in pharmaceutical research and development, including molecular dynamic simulations.
Ben Adams
January 11, 2021
FierceBiotech
We're used to formal clothing expensive hotels and meeting venues that solitary confinement cells look spacious, with the offer of $20 coffees (if spending a minimum of $100), but this year, things are very different.
Conor Hale
January 11, 2021
FierceBiotech
Through a new partnership with Google, Boehringer Ingelheim hopes to harness quantum computing to simulate the body's molecular mechanics.
Nick Paul
December 10, 2020
FierceBiotech
Boehringer Ingelheim has struck a deal to buy NBE-Therapeutics for €1.2 billion ($1.5 billion) to add a ROR1-directed antibody-drug conjugate (ADC) to its pipeline. The deal comes one month after Merck agreed to pay $2.8 billion to acquire VelosBio for its anti-ROR1 ADC.
Amirah Al Idrus
December 9, 2020
FierceBiotech
Boehringer Ingelheim teamed up with German biotech Labor Dr. Merk & Kollegen in 2015 on viral-based therapies. Five years on, it's swallowing up its partner, a move it thinks will boost development of its oncolytic, or cancer-killing viruses, and cancer vaccines. The companies did not disclose financial details.
Boehringer Ingelheim
November 20, 2020
www.prnewswire.com:443
/PRNewswire/ -- Dados da Organização Mundial de Saúde (OMS) indicam que o câncer de pulmão é a neoplasia mais incidente no mundoi. Em 2018, foram mais de 2...
American Diabetes Association
November 16, 2020
www.prnewswire.com:443
/PRNewswire/ -- Seven individuals living with type 2 diabetes and representing a wide range of experiences have been selected as the 2020-21 national...
Bridge Biotherapeutics, Inc.
November 9, 2020
www.prnewswire.com:443
/PRNewswire/ -- On November 9, 2020, Bridge Biotherapeutics (288330 KQ) reported to the Korea Stock Exchange that the Company and Boehringer Ingelheim have...
Press Trust of India
July 31, 2020
@bsindia
Boehringer Ingelheim plans to bring innovative products catering mainly to pets and poultry segment in India, as it expects these verticals to grow in a robust manner over the next few years
Amirah Al Idrus
June 9, 2020
FierceBiotech
The COVID-19 pandemic has thrown a curve ball at the global economy, and the biopharma industry is no exception. Companies are scrambling to develop tests, treatments and vaccines for the disease, while making sure not to neglect their pipelines. We caught up with Ioannis Sapountzis, Boehringer Ingelheim's global head of business development and licensing, to see how the German pharma is handling this.
BioSpace
June 8, 2020
BioSpace
Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to better understand biology and disease-relevant processes is the use of well-characterized small chemical modulators of protein function. The new EUbOPEN consortium aims
Ben Adams
May 15, 2020
FierceBiotech
Boehringer Ingelheim is boosting its early-stage bets while also inking a new deal to work on a therapy against a leading cause of blindness.
May 14, 2020
BioSpace
Boehringer Ingelheim Acquires Northern Biologics' Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio - read this article along with other careers information, tips and advice on BioSpace
May 13, 2020
BioSpace
Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy, a Leading Cause of Blindness Worldwide - read this article along with other careers information, tips and advice on BioSpace
April 14, 2020
WebWire
For the fifth year, Boehringer Ingelheim sponsors the European PRRS Research Award to support applied research for improved control of the PRRS swine disease (Porcine Reproductive and Respiratory Syndrome). Research proposals for the 2020 European PRRS Research Award can be submitted until 1 July 2020. Boehringer Ingelheim will provide three grants of 25,000 euros each to fund research proposals that will generate new and relevant data to better understand this devastating and costly disea...
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.